



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.

All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.

The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.

Antibody-Drug Conjugates (ADCs)

<p>Disitamab vedotin (RC48)</p> <p style="text-align: right;">Cat. No.: HY-P9985</p>	<p>Mal-amido-PEG8-Val-Ala-PAB-SG3200</p> <p style="text-align: right;">Cat. No.: HY-139957</p>
<p>Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.</p> <p style="text-align: right;">Disitamab vedotin</p> <p>Purity: 96.0% Clinical Data: Launched Size: 1 mg, 5 mg</p>	<p>Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a site-specific antibody-drug conjugate (extracted from patent WO2016166300A1).</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>MC-VC-PABC-amide-PEG1-CH2-CC-885</p> <p style="text-align: right;">Cat. No.: HY-145448</p>	<p>SC209</p> <p style="text-align: right;">Cat. No.: HY-144880</p>
<p>MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugates (ADC) based on protein degrading agent (protac molecular glue, etc.).</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Trastuzumab deruxtecan (DS-8201; DS-8201a)</p> <p style="text-align: right;">Cat. No.: HY-138298A</p>	<p>Trastuzumab deruxtecan (solution) (DS-8201 (solution); DS-8201a (solution))</p> <p style="text-align: right;">Cat. No.: HY-138298</p>
<p>Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC).</p> <p style="text-align: right;">Trastuzumab deruxtecan</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC).</p> <p style="text-align: right;">Trastuzumab deruxtecan</p> <p>Purity: 99.40% Clinical Data: Launched Size: 5 mg (10 mg × mL * 500 µL in Aqueous solution)</p>
<p>Trastuzumab emtansine (Ado-Trastuzumab emtansine; PRO132365; T-DM 1)</p> <p style="text-align: right;">Cat. No.: HY-P9921</p>	<p>Ugodotin</p> <p style="text-align: right;">Cat. No.: HY-139591</p>
<p>Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).</p> <p style="text-align: right;">Trastuzumab emtansine</p> <p>Purity: ≥99.40% Clinical Data: Launched Size: 1 mg, 5 mg, 10 mg</p>	<p>Ugodotin is an antibody-drug conjugate. Ugodotin can binds IGF-1R with antitumor activity.</p> <p style="text-align: right;"></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>